Michaelis, Martin, Doerr, Hans Wilhelm, Cinatl, Jindrich (2007) Valproic acid as anti-cancer drug. Current Pharmaceutical Design, 13 (33). pp. 3378-93. ISSN 1381-6128. (doi:10.2174/138161207782360528) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:34084)
| The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. | |
| Official URL: https://doi.org/10.2174/138161207782360528 |
Abstract
The short chain fatty acid valproic acid (VPA, 2-propylpetanoic acid) is approved for the treatment of epilepsia, bipolar disorders and migraine and clinically used for schizophrenia. In 1999, the first clinical anti-cancer trial using VPA was initiated. Currently, VPA is examined in numerous clinical trials for different leukaemias and solid tumour entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing and many questions remain unanswered. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. This review focuses on recent developments regarding the anti-cancer activity of VPA.
| Item Type: | Article |
|---|---|
| DOI/Identification number: | 10.2174/138161207782360528 |
| Subjects: | R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | Divisions > Division of Natural Sciences > Biosciences |
| Depositing User: | Martin Michaelis |
| Date Deposited: | 05 Jun 2013 21:17 UTC |
| Last Modified: | 09 Mar 2023 11:32 UTC |
| Resource URI: | https://kar.kent.ac.uk/id/eprint/34084 (The current URI for this page, for reference purposes) |
University of Kent Author Information
Michaelis, Martin.
| Creator's ORCID: |
 https://orcid.org/0000-0002-5710-5888
|
|---|---|
| CReDIT Contributor Roles: |
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):
Altmetric
Altmetric
